The study, led by L. Falchero of the Hopitaux Nord-Ouest respiratory medicine department in Villefranche-sur-Saone, drew on the prospective national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG, which captured patients newly diagnosed with lung cancer in 2020 and treated in non-academic public hospitals across France. Because these cohorts were designed to enroll consecutive patients nationwide rather than selected referral cases, they offer an unusually faithful snapshot of everyday oncology, in contrast to the carefully curated populations of randomized trials. From a total of 527 patients with small-cell lung cancer, the investigators applied predefined eligibility criteria for G-CSF primary prophylaxis, based on the febrile neutropenia risk of each chemotherapy regimen and on patient-related risk factors, in line with guideline recommendations.

The headline finding is stark in its simplicity. Of the 527 patients, 447, or 84.8 percent, met the predefined eligibility criteria for G-CSF primary prophylaxis. Yet among those eligible patients, only 285, or 63.8 percent, actually received the prophylaxis. In other words, roughly one in three patients for whom guidelines would have supported preventive G-CSF treatment did not get it. A sensitivity analysis, designed to test whether the eligibility definition itself drove the result, confirmed the picture: 439 patients remained eligible under the alternative assumptions, and 281 of them, or 64.0 percent, received prophylaxis, a proportion essentially unchanged from the primary analysis.

Perhaps the most revealing part of the study lies in who did and did not receive the treatment. Patients given G-CSF primary prophylaxis were significantly younger than those who were not, with a mean age of 66.4 years versus 69.4 years, a difference that reached statistical significance at p less than 0.001. Performance status, a standardized measure of a patient’s functional fitness, also separated the groups sharply: 76.3 percent of the prophylaxis group had a good performance status of 0 or 1, compared with 56.0 percent of the non-prophylaxis group, a difference significant at p less than 0.0001. These patterns hint at a systematic bias in prescribing, in which fitter, younger patients are preferentially offered the protective therapy while older and frailer patients, who may in fact be at higher risk of severe complications from febrile neutropenia, are left without it.

The biology behind the recommendation is worth unpacking. G-CSF is a growth factor that stimulates the bone marrow to produce neutrophils, the white blood cells that form the first line of defense against bacterial and fungal infections. Intensive chemotherapy regimens such as carboplatin or cisplatin combined with etoposide, the backbone of small-cell lung cancer treatment, suppress the marrow profoundly, and the resulting nadir in neutrophil counts typically occurs one to two weeks after each cycle. When fever develops during this window of profound neutropenia, mortality and intensive-care admission rates rise substantially, and prior studies cited by the authors have documented both the incidence of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum and the risk factors that predict it, including older age and poor performance status.

Prophylaxis given before the first chemotherapy cycle, so-called primary prophylaxis, is intended to blunt that nadir before it happens, rather than reacting after a first febrile episode. Beyond preventing infections, maintaining the neutrophil count also helps preserve chemotherapy dose intensity, the ability to deliver each planned cycle on schedule and at full dose, which a systematic review and meta-analysis by Lyman and colleagues linked to cancer outcomes. Japanese studies and a 2022 systematic review and meta-analysis published in International Journal of Clinical Oncology have specifically examined the effectiveness and safety of G-CSF primary prophylaxis in lung cancer, supporting its role in this population. French national thoracic oncology guidelines, most recently updated in 2025 by the Auvergne-Rhone-Alpes ARISTOT group, similarly codify when prophylaxis should be offered.

Against that backdrop, the descriptive survival data from the French cohorts are intriguing but must be read with caution, as the authors themselves emphasize. Among patients eligible for primary prophylaxis, median overall survival was 11.2 months in the group that received it, with 3-month and 6-month overall survival of 89.8 percent and 75.4 percent, compared with 8.4 months and 72.8 percent and 63.0 percent respectively in the group that did not. Progression-free survival showed a similar early separation, with 3-month and 6-month rates of 86.7 percent and 56.1 percent in the prophylaxis group versus 70.4 percent and 51.2 percent in the non-prophylaxis group. However, the authors are explicit that these estimates are descriptive only: there were baseline imbalances between the groups, and the survival curves cross at around 12 months, meaning the apparent early advantage cannot be interpreted causally. Sicker patients received less prophylaxis, and sicker patients also die sooner, a classic confounding pattern that no observational analysis of this design can untangle.

The finding of incomplete guideline implementation is not unique to France. A German representative survey published in Supportive Care in Cancer documented gaps in G-CSF guideline adherence among German oncology practices, and a Moroccan single-center experience likewise reported variable use of primary prophylaxis. Physician preference studies add another layer of complexity: a discrete-choice experiment published in BMJ Supportive and Palliative Care found that French physicians weigh factors beyond clinical risk when deciding on febrile neutropenia prophylaxis, and a 2024 questionnaire study on outpatient G-CSF prescribing concluded that considerations beyond clinical factors shape real-world decisions. Practical barriers, including injection logistics, cost concerns, and the perception that elderly or frail patients derive less benefit, likely all contribute to the shortfall observed in the French data.

The therapeutic landscape of small-cell lung cancer has also shifted in ways that raise the stakes of supportive care. The landmark IMpower133 and CASPIAN phase 3 trials established chemoimmunotherapy, combining platinum-etoposide with atezolizumab or durvalumab, as the new first-line standard for extensive-stage disease, and the KBP-ESCAP cohort program itself has documented the impact of immunotherapy on real-life survival in France. In this era, avoiding treatment delays and dose reductions caused by neutropenic complications matters more than ever, since interruptions may compromise the delivery of both cytotoxic and immunotherapeutic components. Safety questions around G-CSF use during concurrent chemoradiotherapy in limited-stage disease, explored in secondary analyses of the CONVERT trial and in retrospective cohort studies of pegylated G-CSF, add nuance but do not negate the case for prophylaxis in patients treated with chemotherapy alone.

What the French analysis ultimately delivers is a benchmark. By quantifying, in a nationwide prospective cohort of 527 consecutive small-cell lung cancer patients, that only about 64 percent of guideline-eligible individuals received G-CSF primary prophylaxis, and by showing that the shortfall concentrates among older patients and those with poorer performance status, the study gives clinicians, hospital administrators and guideline developers a concrete target for quality improvement. The authors suggest that interventions such as electronic medical record prompts, which a 2015 study showed could influence growth factor use, might help close the gap. Whether the survival differences observed in the early months reflect genuine benefit or merely the confounding of patient selection, the message for practice is unambiguous: the decision to withhold prophylaxis should be a deliberate, guideline-informed judgment, not a default driven by age or frailty, because the patients most often left unprotected may be precisely those least able to survive a febrile neutropenic episode.

Subject of Research: Real-world use of G-CSF primary prophylaxis against febrile neutropenia in small-cell lung cancer

Article Title: Real-world use of G-CSF primary prophylaxis in small cell lung cancer: secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG

Article References: Real-world use of G-CSF primary prophylaxis in small cell lung cancer: secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG. (n.d.). https://doi.org/10.1007/s00520-026-11223-7

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11223-7

Keywords: small-cell lung cancer, G-CSF, primary prophylaxis, febrile neutropenia, chemotherapy, guideline adherence, real-world evidence, supportive care, etoposide-platinum, performance status, France, national cohorts

For years, clinical guidelines have drawn a bright line at twenty percent. If a chemotherapy regimen is expected to cause febrile neutropenia in at least one in five patients, guidelines from the American Society of Clinical Oncology, the European Organisation for Research and Treatment of Cancer, and the National Comprehensive Cancer Network recommend giving granulocyte colony-stimulating factor, or G-CSF, prophylactically from the first cycle. This injected growth factor stimulates the bone marrow to keep producing neutrophils through the nadir of each chemo cycle, and randomized evidence shows it reduces both febrile neutropenia and chemotherapy-associated mortality. The trouble is that the twenty percent figure for R-CHOP has rested largely on trial data, and a new systematic review argues that those data may systematically understate what actually happens in ordinary clinics.

The review, published in Supportive Care in Cancer by Jamiel Reyes and Alexander Reyes, took an unusually careful approach to this question. The authors searched MEDLINE, CENTRAL, ClinicalTrials.gov, Europe PMC, Epistemonikos, Lens.org, Google Scholar, and citation trails from inception through 8 September 2026, looking for studies that reported febrile neutropenia incidence in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP or R-CHOP-like immunochemotherapy. The protocol was prospectively registered in PROSPERO, and the team assessed risk of bias with the ROBINS-I tool for observational studies and RoB 2 for randomized trials, then graded the certainty of the evidence using the GRADE framework.

Fifteen studies covering 5,440 patients and 885 febrile neutropenia events made the final analysis. But the authors did something that many meta-analyses of this kind skip: they stratified everything by study design, pooling observational cohorts separately from clinical trials. The rationale is technical but important. Trials and routine-practice cohorts measure the same complication under materially different conditions, and blending them can produce a single number that describes neither setting well. In trials, patients tend to be fitter, monitoring is more intensive, supportive care protocols are more standardized, and prophylactic G-CSF use is often higher and more consistent than in the community.

The observational stratum told a strikingly consistent story. Across ten cohorts enrolling 4,020 patients, the pooled incidence of febrile neutropenia was 19.0 percent, with a 95 percent confidence interval of 17.1 to 21.1 percent. Heterogeneity was low, with an I-squared statistic of just 34 percent, meaning the studies agreed with one another far more than is typical in meta-analyses of this kind. The prediction interval, which estimates where a future study would likely fall, ran from 15.3 to 23.3 percent, and the estimate proved stable across every sensitivity analysis and leave-one-out test the authors performed, including a prespecified analysis restricted to the nine cohorts using core R-CHOP. In other words, no single study was driving the result.

The trial stratum looked very different. Five clinical trials enrolling 1,420 patients yielded a pooled febrile neutropenia incidence of 11.7 percent, but with a confidence interval stretching from 5.7 to 22.7 percent and an I-squared of 79.4 percent, indicating severe heterogeneity. Individual trial estimates ranged from 2.4 to 20.0 percent, a nearly tenfold spread that makes the pooled figure difficult to interpret. The formal comparison between the two designs did not reach conventional statistical significance, with a p-value of 0.051, but the authors note that the difference depended substantially on a single trial. When the large 2013 trial by Cunningham and colleagues comparing 14-day and 21-day R-CHOP schedules was omitted, the trial-stratum estimate shifted to 15.5 percent and the gap between designs essentially disappeared.

What does this mean for the twenty percent threshold? The observational estimate of 19.0 percent sits squarely at, not below, the conventional trigger for primary G-CSF prophylaxis, and its prediction interval crosses well above it. The authors’ conclusion is blunt: in routine practice, approximately one in five adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy develops febrile neutropenia, and trial-derived estimates should not be assumed to represent this real-world burden. For clinicians who have been reassured by trial figures suggesting the risk is closer to one in ten, the message is that the community setting may be considerably riskier than the pages of a phase 3 protocol suggest.

The mechanistic reasons for the discrepancy are not hard to reconstruct. Trial populations are enriched for patients who meet strict eligibility criteria, often excluding older adults with multiple comorbidities, patients with poor performance status, and those with the very risk factors, such as advanced age, elevated lactate dehydrogenase, bulky disease, and low baseline blood counts, that observational studies have repeatedly linked to febrile neutropenia. Trials also tend to enforce prophylactic growth factor use more rigorously and to monitor neutrophil counts on tight schedules, catching problems before they become fevers. Real-world cohorts, by contrast, capture the full spectrum of patients, including elderly and frail individuals who make up a large share of diffuse large B-cell lymphoma diagnoses, and they reflect the uneven adoption of prophylaxis in everyday oncology.

The stakes extend beyond the acute emergency itself. Febrile neutropenia is one of the leading causes of chemotherapy dose reductions and treatment delays, and for a curable disease like diffuse large B-cell lymphoma, compromised dose intensity can translate directly into worse survival. Earlier research, including the INC-EU prospective observational study and analyses of R-CHOP delivery by Pettengell and colleagues, documented how neutropenic complications disrupt treatment schedules and drive hospitalizations. Prophylactic G-CSF, particularly the long-acting pegfilgrastim given once per cycle, has been shown to preserve relative dose intensity, and studies in patients aged 75 and older suggest it reduces mortality in this vulnerable group. If roughly one in five unselected patients experiences a febrile neutropenia event without adequate prophylaxis, the case for applying the guideline threshold generously, rather than treating it as a ceiling, becomes considerably stronger.

The review is not without caveats, and the authors are transparent about them. The between-design difference was not statistically significant at the conventional threshold, and the analysis was reported as an observation rather than a hypothesis test. The registered protocol underwent three amendments, including replacing a comparative outcome with patient-level febrile neutropenia incidence as the primary endpoint and adopting the design stratification during revision, changes the authors documented in the PROSPERO record. All fifteen studies were pooled irrespective of design in a secondary analysis, yielding 17.0 percent with high heterogeneity of 83.3 percent, a figure that illustrates precisely why the stratified approach matters: pooling across designs produces a number with a confidence interval so wide and an I-squared so high that it obscures the two very different realities it averages together. Still, the core observational finding is robust, low-heterogeneity, and consistent with the biological logic of the regimen. As newer first-line options such as polatuzumab vedotin-based therapy enter wider use and add their own myelosuppressive profiles to the mix, the review’s central lesson will only grow in relevance: when deciding who needs prophylactic growth factors, the numbers that count are the ones from the clinic down the street, not just the ones from the trial protocol.

Subject of Research: Febrile neutropenia incidence in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy

Article Title: Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence

Article References: Reyes, J., & Reyes, A. (2026). Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence. Supportive Care in Cancer, 34(10), Article 1065. https://doi.org/10.1007/s00520-026-11301-w

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11301-w

Keywords: diffuse large B-cell lymphoma, febrile neutropenia, R-CHOP, G-CSF, primary prophylaxis, meta-analysis, systematic review, real-world evidence, supportive care, neutropenia, rituximab, clinical trials

The guideline, grounded in evidence-based medicine and expert consensus, uses the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework to classify both the quality of evidence and the strength of each recommendation. Evidence quality ranges from high, where the true effect is likely close to the estimate, to very low, where substantial uncertainty remains. Recommendation strength is binary: strong recommendations signal that benefits clearly outweigh harms, while weak recommendations reflect an uncertain balance. This transparent architecture is intended to help oncologists, hematologists, supportive-care teams, and emergency physicians apply the guidance consistently, with particular attention to tumor types, regimens, and patient populations common in Chinese clinical practice.

The epidemiological data assembled by the guideline authors paint a striking picture of risk. Conventional cytotoxic chemotherapy remains the dominant driver of neutropenic events: taxane-based regimens produce Grade III to IV neutropenia in 45.7 percent of patients, anthracycline-based combinations reach 63.2 percent, and platinum agents cause moderate myelosuppression affecting 38.9 percent of those treated. Newer modalities carry their own hazards. Antibody-drug conjugates such as trastuzumab deruxtecan are associated with neutropenia rates of 23.6 to 41.5 percent, while cyclin-dependent kinase 4/6 inhibitors and PARP inhibitors present an intermediate risk profile spanning 8.5 to 42.1 percent. Even immune checkpoint inhibitors, which are far less directly myelotoxic, still trigger Grade III to IV neutropenia in 3.2 to 15.4 percent of patients, primarily through indirect immune-mediated mechanisms.

Radiotherapy, often overlooked in discussions of myelosuppression, receives detailed quantitative treatment in the guideline. Pelvic irradiation carries the highest risk, with an 18.3 percent incidence of absolute neutrophil counts below 1.0 x 10^9 per liter, followed by thoracic irradiation at 9.7 percent and cranial irradiation at 4.1 percent. Dosimetric analyses reveal a linear correlation between the volume of irradiated active bone marrow and the degree of neutrophil decline: once the irradiated volume exceeds 20 percent, the risk of hematologic toxicity rises 2.3-fold. Concurrent chemoradiotherapy, especially platinum-based regimens combined with abdominopelvic radiation, compounds these effects. Notably, proton therapy can reduce active bone marrow exposure by 30 to 50 percent through Bragg peak optimization, offering a physical route to myeloprotection.

At the cellular level, the guideline explains why these treatments hit the bone marrow so hard. Neutrophils arise from hematopoietic stem cells through sequential differentiation over a maturation period of 7 to 14 days, and the marrow reserve holds roughly 2.5 x 10^12 mature neutrophils, some 12 to 20 times the circulating count. Granulocyte colony-stimulating factor (G-CSF) boosts production three- to fivefold via the JAK2/STAT3 pathway, which is precisely why exogenous G-CSF has become the cornerstone of prophylaxis. Different drug classes injure this system in distinct ways: microtubule-targeting agents like paclitaxel disrupt mitosis in hematopoietic stem cells, platinum compounds induce DNA cross-linking that activates p53-dependent apoptosis in myeloid progenitors, and anthracyclines generate reactive oxygen species that damage marrow stromal cells and the cytokine networks supporting granulopoiesis.

The mechanisms of targeted and immunotherapies are equally mechanistically specific. CDK4/6 inhibitors arrest cycling hematopoietic precursors in the G1 phase, PARP inhibitors impose synthetic lethality on proliferating myeloid cells by crippling DNA repair, and tyrosine kinase inhibitors targeting FLT3 or JAK2 directly interfere with granulocyte-macrophage colony-stimulating factor signaling. Immune checkpoint inhibitors suppress myelopoiesis indirectly by inhibiting the JAK/STAT pathway in CD34-positive progenitor cells through interferon-gamma, while the cytokine release syndrome associated with CAR-T therapy promotes neutrophil sequestration via endothelial activation and tissue infiltration. Understanding these divergent pathways, the authors argue, is essential for anticipating which patients will nadir when, since counts typically bottom out 7 to 14 days after chemotherapy and high-risk regimens warrant twice-weekly monitoring.

Diagnostically, the guideline anchors severity to the National Cancer Institute CTCAE version 5.0 criteria: Grade 1 corresponds to an absolute neutrophil count of 1.5 to 2.0 x 10^9 per liter, Grade 2 to 1.0 to 1.5, Grade 3 to 0.5 to 1.0, and Grade 4 to below 0.5. Febrile neutropenia is defined as an ANC below 0.5 x 10^9 per liter, or below 1.0 with an anticipated fall below 0.5 within 48 hours, accompanied by a single oral temperature of at least 38.3 degrees Celsius, or at least 38.0 degrees sustained for more than one hour. Before the first chemotherapy cycle, clinicians are directed to stratify patients into high-risk (above 20 percent febrile neutropenia risk), intermediate-risk (10 to 20 percent), and low-risk (below 10 percent) categories based on regimen intensity and patient factors such as age over 65, prior cytotoxic exposure, marrow involvement by tumor, poor nutritional status, and impaired hepatic or renal function. High-risk patients should receive primary prophylaxis during the first cycle, and all patients should be re-evaluated before subsequent cycles to determine whether secondary prophylaxis or dose adjustment is needed.

On the pharmacological front, the guideline gives a strong, high-quality-evidence endorsement to pegylated recombinant human G-CSF (PEG-rhG-CSF) as the preferred option for patients at high risk of febrile neutropenia. Randomized controlled trials show the long-acting pegylated formulation is at least as effective as short-acting rhG-CSF, with significantly greater dosing convenience and comparable safety, and cost-effectiveness analyses generally favor it within conventional thresholds. Timing matters: prophylactic PEG-rhG-CSF should be administered within 24 to 72 hours after chemotherapy, and healthcare claims data clearly favor next-day use, with same-day administration associated with significantly higher rates of antibiotic use and chemotherapy modification. The guideline also reviews newer agents, including trilaciclib, which significantly reduced the duration of severe neutropenia in Chinese patients with extensive-stage small cell lung cancer, and plinabulin, which matches pegfilgrastim’s efficacy with same-day dosing and a more favorable safety profile. Intriguingly, structured physical exercise is highlighted as a feasible non-pharmacological complement, with moderate-intensity aerobic activity recommended between chemotherapy cycles for high-risk patients.

Managing the side effects of myeloid growth factors receives its own detailed section. Bone pain, the most common adverse reaction, stems from increased intramedullary pressure and histamine-mediated inflammation and is treated first with NSAIDs such as acetaminophen or ibuprofen, escalating to opioids for severe cases. Allergic reactions can emerge minutes to days after administration and require immediate drug discontinuation, antihistamines, glucocorticoids, and emergency intervention for life-threatening symptoms. Rarer but serious complications include splenic rupture, signaled by left upper quadrant pain, progressive anemia, and hypotension, and pulmonary toxicity, which is why routine co-administration of G-CSF with bleomycin-containing regimens such as ABVD in Hodgkin lymphoma is not recommended. A leukemoid reaction, marked by white-cell counts above 30 x 10^9 per liter with immature cells but no malignant features, typically resolves within 3 to 7 days after stopping the drug.

Finally, the guideline addresses the infectious consequences of febrile neutropenia with a risk-stratified antibiotic strategy. Initial evaluation must identify infection sites, from the gastrointestinal tract and lungs to intravascular devices, and collect timely blood cultures from both peripheral and central sources. Two validated scoring systems guide triage: the MASCC index, where scores of 21 or above indicate low risk of infectious complications, and the CISNE model, which incorporates performance status, comorbidities, mucositis, monocyte count, and stress-induced hyperglycemia. Patients with febrile neutropenia need prompt broad-spectrum antibiotics with antipseudomonal coverage, empiric antifungal therapy reserved for persistent fever unresponsive to antibacterials, and careful de-escalation when risk assessment allows. Looking ahead, the authors point to high-frequency temperature monitoring, microbiome evaluation, immunogenic risk assessment, and machine learning as the next frontier for personalizing antibiotic use, alongside structured patient and caregiver education delivered from the start of therapy and reinforced throughout treatment.

Subject of Research: Clinical guideline for the prevention and management of neutropenia induced by anticancer therapy

Article Title: CACA guidelines for managing cancer therapy-induced neutropenia (2026)

Article References: Xiao, L., Wang, F., Yuan, Y., Xia, S., Qin, W., Zhang, X., Deng, Y., Yuan, X., Ba, Y., Zhang, J., & China Anti-Cancer Association Committee of Neoplastic Supportive-Care (CONS) (2026). CACA guidelines for managing cancer therapy-induced neutropenia (2026). Holistic Integrative Oncology, 5(1), Article 30. https://doi.org/10.1007/s44178-026-00234-3

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00234-3

Keywords: neutropenia, febrile neutropenia, chemotherapy, G-CSF, PEG-rhG-CSF, CACA guidelines, supportive care, radiotherapy, immunotherapy, bone marrow toxicity, antibiotic stewardship, oncology

The answer, published in the journal Supportive Care in Cancer, leans toward restraint. In the retrospective cohort of 303 women treated between August 2021 and April 2025 within the Central European Breast Cancer Collaboration initiative known as CEBCC-102, one hundred patients received primary prophylaxis with granulocyte colony-stimulating factor, or G-CSF, starting from the first cycle of sacituzumab govitecan, while 203 patients began treatment without it. The two groups showed no statistically significant differences in progression-free survival, overall survival, or febrile neutropenia, the feared complication in which fever signals a serious infection during a period of profound immune suppression.

The numbers tell a nuanced story. Median progression-free survival was 4.2 months in the primary prophylaxis group compared with 5.1 months among patients who did not receive upfront growth factor support, a difference that failed to reach statistical significance. Median overall survival was similarly close, at 10.9 versus 11.6 months. Febrile neutropenia struck roughly the same small fraction of patients in both arms, occurring in 4.0 percent of those given primary prophylaxis and 4.4 percent of those managed reactively. Dose reductions of sacituzumab govitecan due to toxicity were also essentially identical, at 36.0 percent and 38.4 percent respectively, suggesting that neither strategy preserved treatment intensity more effectively than the other.

Where the strategies genuinely diverged was in the laboratory. Severe neutropenia, graded as grade 3 or 4 under the standard CTCAE toxicity criteria, was significantly less frequent among patients who received growth factor support from the start, affecting 33.0 percent of that group compared with 50.7 percent of those who did not. That difference, statistically significant at a p-value of 0.005, confirms the biological logic of prophylaxis: stimulating the bone marrow in advance does blunt the depth of chemotherapy-induced myelosuppression. Yet the clinical consequences of that blunting, in terms of fever, infection, dose delays, or survival, simply did not materialize in this cohort, largely because the reactive strategy worked well enough.

That last point is the crux of the study’s most striking observation. Among the 203 patients who began treatment without primary prophylaxis, 74.4 percent subsequently received G-CSF as secondary prophylaxis after experiencing a neutropenic episode. In other words, the reactive approach was not a strategy of neglect; it was a strategy of vigilant monitoring followed by prompt intervention. By the end of treatment, only 52 patients, or 17.2 percent of the entire cohort, had never received growth factor support at all. The authors caution that this high rate of secondary use means the absence of a survival difference should not be read as evidence against G-CSF itself, but rather as a lack of demonstrable advantage for routine upfront administration over timely reactive use.

The regulatory landscape surrounding this question has been shifting in ways that make the new data timely. The National Comprehensive Cancer Network’s Hematopoietic Growth Factors Guidelines classified sacituzumab govitecan as a high-risk regimen for febrile neutropenia, exceeding 20 percent, in Version 1.2026, but reclassified it as intermediate risk, with an estimated febrile neutropenia rate of 10 to 20 percent, in Version 3.2026. For intermediate-risk regimens, guideline logic holds that growth factor use should be guided by individual patient characteristics rather than applied uniformly. The drug’s Summary of Product Characteristics likewise recommends considering primary prophylaxis only in patients at increased risk, including those aged 65 or older, patients with a prior history of neutropenia, poor performance status, organ dysfunction, or multiple comorbidities.

Comparing the Central European cohort with prospective trial data reveals the familiar efficacy-effectiveness gap. In the phase 2 PRIMED trial, which prospectively applied a predefined prophylactic strategy combining G-CSF with loperamide in selected patients with HER2-negative advanced breast cancer, grade 3 or 4 neutropenia occurred in only 16 percent of patients during the first two cycles, well below the rates seen in routine practice. The real-world patients in the CEBCC-102 analysis were treated in the second or later line with greater heterogeneity in prior therapy and supportive care, and their higher neutropenia rates reflect that less selected population. Other real-world studies from the United States, Turkey, the United Kingdom, France, and southern Spain have reported broadly comparable survival figures, with median overall survival hovering around 10 to 11.6 months, reinforcing the external validity of the new findings.

The study also illuminates the economics and logistics of supportive care. Because more than four out of five patients in the cohort ultimately received G-CSF at some point, the analysis suggests a supportive-care-oriented practice style in Central Europe, with relatively liberal growth factor use and comparatively less reliance on dose reduction of the anticancer drug itself. That pattern matters because exposure-response analyses indicate that higher sacituzumab govitecan exposure is associated with a greater probability of response and longer survival, and a Polish real-world study found that initial dose reductions of 20 percent or more were independently linked to shorter progression-free and overall survival without reducing toxicity. Protecting the full approved dose of 10 milligrams per kilogram through optimized supportive care, rather than preemptive dose cutting, appears to be the wiser path for patients who can tolerate it.

Complicating the picture further is the fact that the optimal timing of growth factor administration alongside antibody-drug conjugates remains poorly defined. Sacituzumab govitecan is given on days 1 and 8 of each 21-day cycle, and the conjugate has a longer half-life than its cytotoxic payload, SN-38, leaving uncertainty about which cycle day best accommodates short-acting or long-acting G-CSF. Practical recommendations advise avoiding growth factor administration within 24 hours of cytotoxic treatment, but systematic evidence for the ideal schedule is lacking. Pharmacogenetics adds another layer of complexity: the UGT1A1*28 polymorphism, which impairs metabolism of SN-38, has been associated in some studies with increased toxicity, though the evidence remains inconsistent and testing was not performed in this cohort.

The stakes of getting this right are only set to rise. With the ASCENT-03 trial demonstrating a progression-free survival benefit for sacituzumab govitecan in previously untreated patients and the ASCENT-04 trial supporting its combination with pembrolizumab in the first line for PD-L1-positive disease, the drug is moving earlier into the treatment course, where patients may have less cumulative bone marrow damage but will face longer durations of exposure. The authors of the new study are careful to note that their findings, drawn from later-line patients, should be extrapolated cautiously to first-line use. For now, the message for clinicians managing metastatic triple-negative breast cancer today is one of calibrated vigilance: reserve upfront growth factor support for patients whose individual risk factors justify it, monitor the rest closely, and intervene promptly when blood counts fall. In supportive care, as this large real-world experiment makes clear, more is not always better.

Subject of Research: Primary G-CSF prophylaxis in sacituzumab govitecan treatment of metastatic triple-negative breast cancer

Article Title: Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort

Article References: Mirosława, P., Anna, P.-G., Aleksandra, K., Małgorzata, P., Justyna, Ż., Miloš, H., Renata, S., Hana, Š., Miroslava, M., Agnieszka, M., Karolina, W.-S., Maja, L.-H., Anika, P., Daniel, K., Jan, Š., Iveta, K., Iwona, D., Magdalena, S.-R., Tomasz, C., … Marcin, K. (2026). Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort. Supportive Care in Cancer, 34(10), Article 1030. https://doi.org/10.1007/s00520-026-11274-w

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11274-w

Keywords: sacituzumab govitecan, triple-negative breast cancer, G-CSF, neutropenia, febrile neutropenia, supportive care, real-world evidence, antibody-drug conjugate, chemotherapy-induced neutropenia, CEBCC-102, risk-adapted prophylaxis, oncology

Methimazole is a first-line antithyroid medication that works by blocking the enzyme thyroid peroxidase, thereby curtailing the synthesis of thyroid hormone in patients with autoimmune thyrotoxicosis, most commonly Graves’ disease. The drug is generally well tolerated, but its most feared adverse effect is agranulocytosis, an idiosyncratic hematologic reaction in which the absolute neutrophil count plummets, typically to below 0.5 × 10⁹ per liter. The incidence is low—classically estimated at 0.2 to 0.5 percent of treated patients—but the consequences can be devastating, because neutrophils are the principal cellular effectors of innate immunity against bacteria and fungi. Without them, mucosal barriers in the mouth, throat, and gut become portals for overwhelming infection.

In this case, the patient had been taking methimazole for approximately one month when she presented with fever, pharyngitis, abdominal pain, and diarrhea. The timing is clinically significant: methimazole-induced agranulocytosis most often emerges within the first two to three months of therapy, which is precisely the window in which guidelines recommend vigilance for symptoms such as sore throat and fever. Laboratory evaluation confirmed the severity of her condition, revealing an absolute neutrophil count of just 0.01 × 10⁹ per liter—essentially a complete absence of circulating neutrophils—alongside markedly elevated inflammatory markers indicating a systemic inflammatory response already in progress.

What distinguished this case from the typical presentation of drug-induced agranulocytosis was what imaging revealed next. Computed tomography confirmed an ileocolic intussusception, with the terminal portion of the small intestine having invaginated into the colon. Intussusception is common in infants, where it is usually idiopathic, but in adults it is rare and almost always associated with a pathological lead point such as a polyp, tumor, or—critically in this patient’s situation—disordered motility and inflammatory change driven by severe sepsis. Even more alarming, surgical findings showed transmural necrosis of the involved bowel segment, meaning the intestinal wall had died through its full thickness, a condition that rapidly becomes fatal without resection.

The clinical team faced a genuine dilemma. Emergency surgery in a patient with profound neutropenia and septic shock carries extraordinary risks: the patient has minimal capacity to heal, to fight surgical-site infection, or to withstand the physiological insult of laparotomy. Profound neutropenia has traditionally been regarded as a relative contraindication to major emergency surgery. Yet the authors argue that when septic shock results from intestinal necrosis, the necrotic bowel itself is the source of the sepsis, and no amount of antibiotics will achieve cure without source control. The patient underwent an emergency ileocolic resection with a temporary ileostomy, removing the dead segment and diverting the fecal stream to protect the anastomosis.

Perioperative and postoperative management was aggressively multidisciplinary. The team administered broad-spectrum intravenous antibiotics to cover the gut flora flooding into tissues and bloodstream, and administered granulocyte colony-stimulating factor, or G-CSF, a recombinant growth factor that stimulates the bone marrow to produce and release neutrophils. G-CSF has become standard supportive care in antithyroid drug-induced agranulocytosis, shortening the duration of neutropenia, although its effect on mortality in septic neutropenic patients remains debated. The patient also required multi-organ support in the intensive care unit, reflecting the degree to which septic shock had compromised her cardiovascular and other organ systems.

The authors place their case in the context of a literature review of comparable reports, noting that gastrointestinal complications of agranulocytosis—ranging from necrotizing enterocolitis-like presentations to sepsis-driven bowel perforation—are exceedingly uncommon but well documented. The mechanism they propose for the intussusception is instructive: sepsis and severe inflammation can disrupt normal intestinal peristalsis, creating uncoordinated, spastic bowel contractions. In an adult bowel already weakened by inflammatory injury and mucosal breakdown, these dyskinetic segments can serve as the lead point for telescoping. This reframes intussusception not merely as a mechanical accident but as a potential downstream consequence of systemic immunoparalysis and septic physiology.

The broader lessons of the case concern monitoring and clinical decision-making. The authors emphasize the critical need for vigilant hematologic surveillance in patients starting methimazole, particularly during the first months of therapy. Current practice varies internationally: routine serial white cell counts are not universally recommended because agranulocytosis is unpredictable and idiosyncratic, unrelated to dose in most cases, but all guidelines agree that any patient on antithyroid medication who develops fever or sore throat must have an urgent differential blood count. The message for patients is equally important—symptoms that might suggest an ordinary upper respiratory infection can, in this context, signal a hematologic emergency.

Equally consequential is the paper’s stance on surgery in neutropenic sepsis. By demonstrating a successful outcome after emergency bowel resection in a patient whose neutrophil count was essentially zero, the authors argue that profound neutropenia should not be treated as an absolute contraindication to life-saving source control. The decision framework they describe is one of weighing the mortality of untreated necrotic bowel—approaching certainty—against the substantial but potentially survivable risks of surgery supported by antibiotics, G-CSF, and intensive care. Their conclusion that a multidisciplinary approach involving emergency physicians, endocrinologists, hematologists, surgeons, and intensivists is essential for successful outcomes reflects a growing consensus in the management of complex drug toxicities.

The case also carries a public health dimension. Hyperthyroidism affects a substantial fraction of the population, particularly women, and antithyroid drugs remain the standard initial therapy worldwide, especially in regions where radioactive iodine and surgery are deferred or unavailable. Agranulocytosis, while rare, is a reminder that even familiar, decades-old medications demand respect for their idiosyncratic risks. The Fujian team’s detailed documentation—supported by funding from the Joint Funds for the Innovation of Science and Technology of Fujian Province and approved by their institutional ethics committee with the patient’s written informed consent—adds a valuable data point to a sparse literature, and offers clinicians a template for recognizing and responding to one of the most dangerous intersections of endocrinology, hematology, and emergency surgery.

Subject of Research: Methimazole-induced agranulocytosis complicated by sepsis and ileocolic intussusception

Article Title: Methimazole-induced agranulocytosis complicated by sepsis and ileocolic intussusception: a case report and literature review

Article References: Zhu, X., Zhang, H., Lin, J., Pang, M., Zhang, X., Dong, Y., Huang, Y., & Li, Y. (2026). Methimazole-induced agranulocytosis complicated by sepsis and ileocolic intussusception: a case report and literature review. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02569-4

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02569-4

Keywords: methimazole, agranulocytosis, sepsis, intussusception, hyperthyroidism, adverse drug reaction, G-CSF, neutropenia, thyrotoxicosis, emergency surgery, BMC Endocrine Disorders, case report